6HV1 Stock Chart & Stats
€4.22
€0.10(2.33%)
At close: 4:00 PM EDT
€4.22
€0.10(2.33%)
Day’s Range― - ―
52-Week Range€1.01 - €9.35
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€318.65M
Enterprise Value€436.47M
Total Cash (Recent Filing)€107.80M
Total Debt (Recent Filing)€934.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 05, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding96,728,910
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.37
Price to Sales (P/S)0.00
P/FCF Ratio-8.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.90Price Target Upside110.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.62
Revenue Forecast (FY)€2.56M
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-free balance sheet gives Rezolute greater financial flexibility while it advances clinical programs and manages ongoing losses. The sizable equity base provides a buffer against near-term financing pressure, although it does not eliminate the need to fund continued development.
Clinical ProgressCompletion of the pivotal upLIFT enrollment milestone advances ersodetug toward a potentially important readout in tumor hyperinsulinism. Interim responder results and reported tolerability provide encouraging clinical evidence that could support further regulatory and commercial development.
Regulatory PathwayThe FDA’s willingness to proceed with a pre-BLA discussion keeps a regulatory pathway open for congenital hyperinsulinism despite earlier endpoint misses. Clinically relevant glucose-monitoring improvements and extension-study data may help shape a broader filing strategy.
Bears Say
No RevenueRezolute has not yet established commercial revenue, leaving its business model dependent on clinical progress and future regulatory approval. Until a product reaches the market, the company lacks recurring operating income to fund research, administration, and expansion.
Widening LossesThe sharp expansion in net losses indicates that Rezolute’s cost base and development investment are rising faster than any operating contribution. Persistent losses reduce internal funding capacity and increase the importance of successful clinical execution and eventual product commercialization.
Cash BurnSustained negative free cash flow shows that Rezolute is consuming substantial cash while its pipeline remains pre-commercial. The worsening burn trajectory can constrain strategic flexibility over the next several quarters and may require additional funding to maintain development activities.
Rezolute News
6HV1 FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was €1.01 and its highest was €9.35 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is €318.65M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Sep 24, 2026. The company reported -€0.178 earnings per share for the quarter, missing the consensus estimate of -€0.132 by -€0.046.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.17.
How many shares outstanding does Rezolute have?
Rezolute has 96,728,910 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -€0.178 in its last earnings report, missing expectations of -€0.132. Following the earnings report the stock price went down -0.585%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in DE:6HV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.90 (110.88% Upside)
€8.90 (110.88% Upside)
Blogger Sentiment
Neutral
DE:6HV1 Sentiment 50%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.23%
12-Months-Change
Fundamentals
Return on Equity
-62.99%
Trailing 12-Months
Asset Growth
-35.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rezolute
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
6HV1 Stock 12 Month Forecast
Average Price Target
€8.90
▲(110.88% Upside)